Compare Live Nation Entertainment, Inc. (LYV) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs ResMed Inc. — how do they compare? Live Nation Entertainment, Inc. trades at $183.14 (market cap $42.71B), while ResMed Inc. trades at $220 (market cap $32.61B). The key difference: Live Nation Entertainment, Inc. is the larger of the two by market cap, and ResMed Inc. pays a 1.17% dividend while Live Nation Entertainment, Inc. pays none. Which is the better fit depends on your goals.
| LYV | RMD | |
|---|---|---|
Market Cap | $42.71B | $32.61B |
Sector | Industrials | Health |
52-Week High | $186.59 | $293.73 |
52-Week Low | $125.61 | $182.82 |
Enterprise Value | $44.92B | $31.97B |
Dividend Yield | — | 1.17% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
